Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed

NCT ID: NCT00003053

Last Updated: 2013-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

750 participants

Study Classification

INTERVENTIONAL

Study Start Date

1994-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare cisplatin and etoposide with no chemotherapy in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer that has been surgically removed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Assess the efficacy of the combination of cisplatin and etoposide after radical surgery in prolonging the relapse free and overall survival for stages I, II, and IIIA non-small cell lung cancer.

OUTLINE: This a randomized study (treatment vs no treatment). Patients are stratified according to sex and to stage of disease (I vs II vs IIIA).

Patient receives cisplatin and etoposide on days 1-3, every 28 days, for 3 cycles. Patient may receive radiation therapy after surgery at the discretion of the physician.

PROJECTED ACCRUAL: Approximately 750 patients will be accrued over 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stage I non-small cell lung cancer stage II non-small cell lung cancer stage IIIA non-small cell lung cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cisplatin

Intervention Type DRUG

etoposide

Intervention Type DRUG

adjuvant therapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically proven stage I, II, or IIIA non-small cell lung cancer after radical surgery
* No evidence of lymphonodal enlargement during postsurgical chest CT scan

PATIENT CHARACTERISTICS:

Age:

* 70 and under

Performance status:

* ECOG 0-2

Life expectancy:

* Not specified

Hematopoietic:

* WBC at least 3,500/mm3
* Platelet count at least 100,000/mm3

Hepatic:

* Not specified

Renal:

* Creatinine no greater than 1.5 times the upper limit of normal

Pulmonary:

* FEV1 at least 1 liter

Other:

* Less than 10% weight loss in the past 3 months
* No prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* Not specified

Endocrine therapy:

* Not specified

Radiotherapy:

* Not specified

Surgery:

* Radical surgery required
Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Institute of Oncology

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonio Nicolucci, MD

Role: STUDY_CHAIR

Consorzio Mario Negri Sud

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

George Papanicolaou General Hospital

Thessaloniki, , Greece

Site Status

Ospedale Bassini

Balsamo Cinisello, , Italy

Site Status

Universita Degli Studi di Bari Policlinico

Bari, , Italy

Site Status

Spedali Civili

Brescia, , Italy

Site Status

Ospedale Oncologico A. Businco

Cagliari, , Italy

Site Status

Cattedra di Oncologia Medica - Universita degli Studi di Cagliari

Cagliari, , Italy

Site Status

Ospedale San Michele

Cagliari, , Italy

Site Status

Ospedale Sant Anna

Como, , Italy

Site Status

Ospedale Valduce

Como, , Italy

Site Status

Ospedale Di Conselice

Conselice, , Italy

Site Status

Ospedale Civile Cosenza

Cosenza, , Italy

Site Status

Ospedale Maggiore Crema

Crema, , Italy

Site Status

Ospedale Santa Croce

Cuneo, , Italy

Site Status

Ospedale Civile Feltre

Feltre, , Italy

Site Status

Universita di Ferrara

Ferrara, , Italy

Site Status

Universita Degli Studi di Firenze - Policlin. di Careggi

Firenze (Florence), , Italy

Site Status

Policlinico di Careggi

Firenze (Florence), , Italy

Site Status

U.S.L. 10 Villa Ognissanti

Florence, , Italy

Site Status

Istituto Nazionale per la Ricerca sul Cancro

Genoa (Genova), , Italy

Site Status

Ospedale San Martino/Cliniche Universitarie Convenzionate

Genoa (Genova), , Italy

Site Status

Ospedale Galliera Oncologia

Genova (Genoa), , Italy

Site Status

Ospedale Di Gorgonzola

Gorgonzola, , Italy

Site Status

Ospedale Alessandro Manzoni

Lecco, , Italy

Site Status

Ospedale Legnago USSL 21

Legnago, , Italy

Site Status

Ospedale Maggiore Lodi

Lodi, , Italy

Site Status

Ospedale Umberto I

Lugo DI Romagna, , Italy

Site Status

U.S.S.L. 72 Magenta

Magenta, , Italy

Site Status

Carlo Poma Hospital

Mantova, , Italy

Site Status

Ospedale Di Predabissi Melegnano

Melegnano, , Italy

Site Status

Azienda USSL NO 8

Merate, , Italy

Site Status

Instituto Di Oncologia

Messina, , Italy

Site Status

Ospedale Civile Umberto I

Mestre, , Italy

Site Status

Ospedale San Giuseppe

Milan, , Italy

Site Status

Consorzio Provinciale Antitubercolare

Milan, , Italy

Site Status

Istituto Scientifico H.San Raffaele

Milan, , Italy

Site Status

Istituto Di Science Biomediche San Paolo

Milan, , Italy

Site Status

Casa Di Cura San Ambrogio

Milan, , Italy

Site Status

Ospedale San Carlo Borromeo

Milano (Milan), , Italy

Site Status

Ospedale Luigi Sacco

Milano (Milan), , Italy

Site Status

Ospedale Maggiore Ca'Granda

Milano (Milan), , Italy

Site Status

Ospedale Santa Croce

Moncalieri, , Italy

Site Status

Nuovo Ospedale San Gerardo

Monza, , Italy

Site Status

Ospedale Civile Asilo Vittoria

Mortara, , Italy

Site Status

Istituto Nazionale per lo Studio e la Cura dei Tumori

Naples, , Italy

Site Status

Federico II University Medical School

Naples (Napoli), , Italy

Site Status

Istituto Tumori/Fondazione Pascale

Naples (Napoli), , Italy

Site Status

Ospedale Vincenzo Monaldi

Napoli, , Italy

Site Status

Ospedale C. Ascalesi

Napoli, , Italy

Site Status

Ospedale Civile Negrar

Negrar, , Italy

Site Status

Azienda Ospedaliera di Padova

Padova (Padua), , Italy

Site Status

University of Padua

Padua, , Italy

Site Status

Ospedale Civico E Benefratelli

Palermo, , Italy

Site Status

Ospedale Maggiore Parma

Parma, , Italy

Site Status

Ospedale Torrette University Ancona

Parma, , Italy

Site Status

Ospedale Silvestrini

Perugia, , Italy

Site Status

Ospedale Agnelli

Pinerolo, , Italy

Site Status

Ospedale Sta. Maria Delle Croci

Ravenna, , Italy

Site Status

Azienda Ospedaliera

Reggio Emilia, , Italy

Site Status

Ospedale Civile Rho

Rho, , Italy

Site Status

Istituti Fisioterapici Ospitalieri - Roma

Rome, , Italy

Site Status

Ospedale San Filippo Neri

Rome, , Italy

Site Status

Ospedale Carlo Forlanini

Rome, , Italy

Site Status

Ospedale S. Camillo-Forlanini

Rome, , Italy

Site Status

Azienda Policlinico Umberto Primo

Rome, , Italy

Site Status

Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore

Rome, , Italy

Site Status

Policlinico Militare Celio

Rome, , Italy

Site Status

ASL NO. 1 Imperiese

Sanremo, , Italy

Site Status

Consorzio Mario Negri Sud

Santa Maria Imbaro, , Italy

Site Status

Azienda USSL No 4

Saronno, , Italy

Site Status

Istituto Clinica Medica

Sassari, , Italy

Site Status

Ospedale Sesto San Giovanni

Sesto San Giovanni, , Italy

Site Status

Azienda Ospedaliera S. Maria

Terni, , Italy

Site Status

Ospedale Generale Prov. Boldrini

Thiene, , Italy

Site Status

Dispensario Igiene Sociale

Toino, , Italy

Site Status

Clinica Universita

Torino, , Italy

Site Status

Universita di Torino

Torino, , Italy

Site Status

Ospedale S. Chiara

Trento, , Italy

Site Status

Ospedale San Isidoro

Trescore Balneario, , Italy

Site Status

Ospedale General Regional Ca Foncello

Treviso, , Italy

Site Status

Ospedale Maggiore dell' Universita

Trieste, , Italy

Site Status

Ospedale Cattinara

Trieste, , Italy

Site Status

Cattedra di Immunologia Clinica

Turin (TO), , Italy

Site Status

Universita Degli Studi di Udine

Udine, , Italy

Site Status

Casa di Cura S. Maria

Varese, , Italy

Site Status

Ospedale San Bortolo

Vicenza, , Italy

Site Status

Inha University Hospital

Incheon, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece Italy South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CNR-NICO-01

Identifier Type: -

Identifier Source: secondary_id

EU-97010

Identifier Type: -

Identifier Source: secondary_id

CDR0000065700

Identifier Type: -

Identifier Source: org_study_id